Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).

7012 Background: Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton’s tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO ...